SCHEMBL529309

SCHEMBL529309

CCOC(=O)c1cnc2ccc(Br)cc2c1N1CCC(N)CC1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
MAPK10 P53779 1/20 0.59
ALDH1A1 P00352 4/20 0.58
MAPT P10636 6/20 0.56
NPSR1 Q6W5P4 4/20 0.56
GAA P10253 2/20 0.56
MAPK1 P28482 1/20 0.53
RXFP1 Q9HBX9 3/20 0.52
LMNA P02545 1/20 0.52
HTT P42858 2/20 0.51
TP53 P04637 2/20 0.49
POLB P06746 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15191414 0.90 TP53 (0.59) MEN1KMT2AMAPK10ALDH1A1MAPT
SCHEMBL15190695 0.90 MEN1 (0.57) MEN1KMT2AMAPK10ALDH1A1MAPT
SCHEMBL530165 0.87 MELK (0.57) MEN1KMT2AMAPK10ALDH1A1MAPT
SCHEMBL15191218 0.87 MEN1 (0.55) MEN1KMT2AMAPK10ALDH1A1MAPT
SCHEMBL4587494 0.86 RXFP1 (0.66) MEN1KMT2AMAPK10ALDH1A1MAPT
SCHEMBL27907407 0.84 SSTR2 (0.49) MEN1KMT2AALDH1A1NPSR1HTT
SCHEMBL529272 0.83 MAPT (0.55) MEN1KMT2AMAPK10ALDH1A1MAPT
SCHEMBL529323 0.81 MEN1 (0.54) MEN1KMT2AMAPK10ALDH1A1MAPT
SCHEMBL15191243 0.80 MEN1 (0.50) MEN1KMT2AMAPK10ALDH1A1MAPT
SCHEMBL529026 0.79 MAPK1 (0.63) NPSR1GAAMAPK1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120749-B2 Quinoline derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2015-09-01 US disclosed
US-9120749-B2 Quinoline derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2015-09-01 US disclosed
US-9120749-B2 Quinoline derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2015-09-01 US disclosed
US-20130217671-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2013-08-22 US disclosed
US-20130217671-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2013-08-22 US disclosed
US-20130217671-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2013-08-22 US disclosed
EP-2597955-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME OncoTherapy Science, Inc. (JP) 2013-06-05 EP disclosed
WO-2012016082-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2012-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217671-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME MELK, NADK, NEK1 MEN1 543/4885KMT2A 551/4885MAPK10 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.